LG3
A fragment of the LG3 domain of perlecan cleaved by BMP-1, enabling non-invasive monitoring of basement membrane remodeling and fibrotic activity in chronic kidney diseases. In heparin plasma and urine only.
Key features and values
- Quantifies LG3 fragments indicative of basement membrane remodeling.
- Reflects fibrotic activity associated with chronic kidney diseases.
- Provides a non-invasive measure of extracellular matrix dynamics.
- Supports monitoring of disease progression and response to therapies targeting fibrosis.
- Applicable in research on diseases characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
- In heparin plasma and urine only.
Description
The LG3 biomarker assay measures specific fragments of the LG3 domain of perlecan resulting from BMP-1-mediated cleavage, serving as an indicator of basement membrane remodeling and fibrotic activity. This non-invasive assay provides insights into tissue remodeling processes associated with chronic kidney diseases. By quantifying LG3 degradation products, the assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue fibrosis and damage. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover and fibrotic tissue remodeling.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
